Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Harvard Researcher Wins 2019 AANEM Scientific Impact Award for Study of Fingolimod in ALS

A Harvard Medical School professor and scientist, Sabrina Paganoni, has won the 2019 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Scientific Impact Award for her work in a Phase 2a trial testing fingolimod as a potential treatment for amyotrophic lateral sclerosis (ALS). Fingolimod is marketed as Gilenya (by Novartis),…

Study Supports Cdk5 as Therapeutic Target for ALS

Inhibition of a protein called Cdk5 in the brain increases lifespan and improves motor function in mice with amyotrophic lateral sclerosis (ALS), a new study reports. This evidence supports a potential role for Cdk5 in the progression of ALS and opens new avenues as a potential therapeutic target for…

Klotho Protein Protects Brains of ALS Mice, Study Suggests

The klotho protein may have brain-protecting effects in amyotrophic lateral sclerosis (ALS), according to a study in mice that may become a basis for developing new therapies. The study, “Klotho Is Neuroprotective in the Superoxide Dismutase (SOD1G93A) Mouse Model of ALS,” was published in the Journal…

Copper-ATSM Prevented Motor Neuron Loss in SALS Mouse Model

Copper-ATSM — a compound originally used as an imaging agent — prevented motor neuron loss and reduced brain inflammation in a mouse model of sporadic amyotrophic lateral sclerosis (ALS), a study showed. The study, titled “Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in…